Much debated controversies of diffuse low-grade gliomas

Neuro-Oncology

Volumn 17, Issue 3, 2015, Pages 323-326

  Zadeh, Gelareh ^c   Khan, Osaama H ^c   Vogelbaum, Michael ^a   Schiff, David ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; GUANINE; ISOCITRATE DEHYDROGENASE; LOMUSTINE; PHOSPHATE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ANAPLASTIC CARCINOMA; BRAIN FUNCTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL EFFECTIVENESS; COGNITION; CRANIOTOMY; DIFFUSE LOW GRADE GLIOMA; DISEASE SEVERITY; ELECTROSTIMULATION; FOLLOW UP; GLIOMA; HUMAN; IMAGE ANALYSIS; INCIDENCE; INTRAOPERATIVE ELECTROSTIMULATION MONITORING; LANGUAGE TEST; MALIGNANT TRANSFORMATION; MEAN TUMOR DIAMETER; MEDICAL DECISION MAKING; NERVE CELL PLASTICITY; NEUROPSYCHOLOGICAL TEST; NEUROREHABILITATION; OVERALL SURVIVAL; PATIENT CARE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; REOPERATION; REVIEW; SAFETY; SURGICAL TECHNIQUE; THERAPY DELAY; TUMOR LOCALIZATION; TUMOR VOLUME; WAIT AND SEE STRATEGY; BRAIN NEOPLASMS; PATHOLOGY;

BRAIN NEOPLASMS; GLIOMA; HUMANS;

EID: 85018611921     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou368     Document Type: Review

References (37)

1. Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients. Acta Neurochir (Wien). 2009;151(11):1359–1365.
2. Berger MS, Deliganis AV, Dobbins J, et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74(6):1784–1791.
3. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol. 1997;34(1):85–101.
4. Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005;103(6):1227–1233.
5. Duffau H. Surgery of low-grade gliomas: towards a ‘functional neurooncology’. Curr Opin Oncol. 2009;21(6):543–549.
6. Durmaz R, Vural M, Isildi E, et al. Efficacy of prognostic factors on survival in patients with low grade glioma. Turk Neurosurg. 2008; 18(4):336–344.
7. Hardesty DA, Sanai N. The value of glioma extent of resection in the modern neurosurgical era. Front Neurol. 2012;3:140.
8. Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. J Neurosurg. 2012;117(6):1039–1052.
9. Maiuri F, Del Basso De Caro ML, Iaconetta G, et al. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl Neurochir. 2006;67(4):204–209.
10. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700–707; author reply 707–708.
11. Nakamura M, Konishi N, Tsunoda S, et al. Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology. 2000;58(2):108–116.
12. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–764; discussion 264–266.
13. Sanai N, Polley MY, Berger MS. Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg. 2010;112(1):1–9.
14. Sankar T, Moore NZ, Johnson J, et al. Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. J Neurosurg. 2012; 116(6):1172–1181.
15. Shaw EG, Scheithauer BW, O’Fallon JR, et al. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg. 1992;76(3):428–434.
16. Shaw EG, Tatter SB, Lesser GJ, et al. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol. 2004;31(5):653–658.
17. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–1345.
18. van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998; 64(5):581–587.
19. Soffietti R, Chio A, Giordana MT, et al. Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery. 1989;24(5):686–692.
20. National Comprehensive Cancer Network. Central nervous system cancers. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
21. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol. 2006;24(8):1236–1245.
22. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881–1888.
23. Krieg SM, Schnurbus L, Shiban E, et al. Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study. BMC Cancer. 2013;13:51.
24. Kim SS, McCutcheon IE, Suki D, et al. Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients. Neurosurgery. 2009;64(5):836–845; discussion 345–346.
25. Duffau H, Capelle L, Sichez N, et al. Intraoperative mapping of the subcortical language pathways using direct stimulations. An anatomo-functional study. Brain. 2002;125(Pt 1):199–214.
26. Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2013;15(5):595–606.
27. Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137(Pt 2):449–462.
28. Baumert B, Mason W, Ryan G, et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033–26033). Paper presented at: ASCO 2013. Abstract number 2007.
29. Buckner JC, Pugh SL, Shaw EG, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. Paper presented at: ASCO 2014. Abstract number 2000.
30. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–193.
31. Fisher B, Lui J, Macdonald D, et al. A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: preliminary results of RTOG 0424. Paper presented at: ASCO 2013. Abstract number 2008.
32. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009;15(1):330–337.
33. Pouratian N, Gasco J, Sherman JH, et al. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2007;82(3):281–288.
34. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091.
35. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28(30):4601–4608.
36. Deekonda P, Bernstein M. Decision making, bias, and low grade glioma. Can J Neurol Sci. 2011;38(2):193–194.
37. Hayhurst C, Mendelsohn D, Bernstein M. Low grade glioma: a qualitative study of the wait and see approach. Can J Neurol Sci. 2011;38(2):256–261.